Biotech
News Alert: GenSpera (OTCQB:GNSZ) Announces
Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by
World Health Organization
Mipsagargin
Contains New Pre-Stem “Gargin”, Defining a Unique Pharmacologic Group Unlike
Any Drug Currently or Previously on the Market
SAN
ANTONIO, Texas, September 3, 2014 – (Investorideas.com
Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in
developing prodrug therapeutics for the treatment of cancer, today announced
that the World Health Organization’s (WHO) International Nonproprietary Name
(INN) group has recommended the generic name “mipsagargin” (mip sa gar’ jin)
for its lead drug candidate, also known as G-202, currently in Phase II
clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma
(brain cancer). Mipsagargin was also recommended by the United States Adopted
Names Council (USAN) of the American Medical Association.
Craig
Dionne, PhD, GenSpera's CEO, spoke to the significance of this issuance, “We
are pleased that the INN division of WHO and the USAN Council recognized the
unique nature of mipsagargin by affording it the new suffix, or pre-stem, of
“gargin.” The WHO issues approximately 160 name recommendations per year with
only 1-2% having new suffixes. New suffixes are generally given to compounds
with a unique mechanism of action or structure and serve to define such
compound as the first in a possible new class of pharmacological agents. We
believe mipsagargin’s name recommendation is the result of G-202’s novel nature and our innovative approaches to cancer
therapy.”
GenSpera
recently released interim results from the Phase Ib and ongoing Phase II study
in hepatocellular carcinoma (HCC) patients who had previously progressed on, or
who were intolerant of sorafenib. Data showed 80% of patients treated with
mipsagargin had stable disease (no tumor growth) at two months and 50% of
patients exhibited stable disease at four months on study. In addition, imaging
analysis demonstrated an impressive blockade of tumor blood flow in the single
patient evaluated by this method to date.
About
Nonproprietary Names
Obtaining
a nonproprietary (generic) name is a required part of bringing a new drug to
market. The
generic names of pharmacologically-related substances demonstrate their
relationship by using a common "stem". Using common stems, medical
practitioners, pharmacists, or people dealing with pharmaceutical products are
able to recognize that the substance belongs to a group of substances having
similar pharmacological activity. The generic name mipsagargin includes a novel
pre-stem, “gargin”, indicating that it is unlike any named drug currently or
previously on the market or in development. The pre-stem “gargin” may become an
established stem over time, usually as other later developed drugs are
recognized to be related in structure or activity to mipsagargin.
Each
International Nonproprietary Name is a unique name that is globally recognized
and is public property.
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/09031.asp
About GenSpera
GenSpera’s
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a prodrug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA,
which is found at high levels in the vasculature of liver and glioblastoma
cancers and in the vasculature of almost all other solid tumors. Mipsagargin is
therefore expected to have potential efficacy in a wide variety of tumor types.
Mipsagargin
Phase II clinical trials are underway in both hepatocellular carcinoma and
glioblastoma patients.
For
more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Watch
the Corporate Video:
Cautionary Statement Regarding Forward
Looking Information
This news
release may contain forward-looking statements. Investors are cautioned that
statements in this press release regarding potential applications of GenSpera’s
technologies constitute forward-looking statements that involve risks and
uncertainties, including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual property
rights. Actual results may differ materially from the results anticipated in
these forward-looking statements. Additional information on potential factors
that could affect our results and other risks and uncertainties will be
detailed from time to time in GenSpera’s periodic reports filed with the
Securities and Exchange Commission.
CONTACT:
Company:
Craig Dionne, PhD,
CEO
GenSpera, Inc. (210) 479-8112
Investors:
Steve
Gersten
Capital
Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
Dawn
Van Zant
(800)
665 0411
Disclaimer/Disclosure:
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights. Investorideas
is a news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor
Ideas for PR and news publication effective June 18, 2014 (compensation of five
thousand per month and average of eleven thousand five hundred 144 shares per
month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment